Ameriprise Financial Inc. boosted its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 27.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,545 shares of the company's stock after acquiring an additional 6,951 shares during the period. Ameriprise Financial Inc.'s holdings in DaVita were worth $4,867,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in DaVita during the fourth quarter worth about $41,000. Coppell Advisory Solutions LLC boosted its stake in shares of DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after acquiring an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan acquired a new stake in shares of DaVita during the fourth quarter valued at $55,000. Venturi Wealth Management LLC boosted its stake in shares of DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after acquiring an additional 152 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after acquiring an additional 131 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.
DaVita Stock Down 0.3%
Shares of DVA stock traded down $0.45 during trading hours on Thursday, reaching $136.21. The company had a trading volume of 723,921 shares, compared to its average volume of 821,900. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a twelve month low of $131.76 and a twelve month high of $179.60. The company has a market capitalization of $10.28 billion, a P/E ratio of 12.68, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The stock's fifty day simple moving average is $144.38 and its 200 day simple moving average is $153.00.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. DaVita's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.26 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently commented on DVA. Barclays increased their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Truist Financial reduced their price target on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, DaVita currently has an average rating of "Hold" and a consensus price target of $164.50.
View Our Latest Analysis on DVA
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
